Literature DB >> 26511990

The preventive effect of vaccine prophylaxis on severe respiratory syncytial virus infection: A meta-analysis.

Tongna Zhu1, Chuanlong Zhang2, Li Yu1, Jingxian Chen1,3, Huan Qiu1, Weiwei Lyu1, Shenghai Huang4,5.   

Abstract

Respiratory syncytial virus (RSV) is the key underlying cause of acute lower respiratory tract infection in infants; however, no licensed vaccine against RSV infection is currently available. This study was undertaken to assess the preventive effect of vaccine on RSV infection. In this metaanalysis, 1,792 published randomized clinical trials of RSV vaccines from Jan 1973 to Sep 2015 were examined. Among thirteen studies that met the inclusion criteria, eleven studies estimated the impact of RSV vaccines and four studies estimated the effect of adjuvants. The odds ratios (ORs) were 0.31 (95% CI, 0.15-0.67) and 0.62 (95% CI, 0.29-1.34), respectively. We found that RSV subunit vaccines can significantly reduce the incidence of RSV infection and that whether vaccination with adjuvant therapy was an effective strategy still remained to be studied. This analysis of the preventive effect of vaccines on RSV infection has direct applications for the prevention of RSV infections.

Entities:  

Keywords:  meta-analysis; respiratory syncytial virus (RSV); vaccine prophylaxis

Mesh：

Substances：

Year:  2015        PMID： 26511990      PMCID： PMC8200922          DOI： 10.1007/s12250-015-3630-3

Source DB:  PubMed          Journal:  Virol Sin        ISSN： 1995-820X            Impact factor:   4.327


  32 in total

Review 1.  Pharmacologic advances in the treatment and prevention of respiratory syncytial virus.

Authors:  Kerry M Empey; R Stokes Peebles; Jay K Kolls
Journal:  Clin Infect Dis       Date:  2010-05-01       Impact factor: 9.079

2.  Anti-G protein antibody responses to respiratory syncytial virus infection or vaccination are associated with inhibition of G protein CX3C-CX3CR1 binding and leukocyte chemotaxis.

Authors:  Jennifer L Harcourt; Ruth A Karron; Ralph A Tripp
Journal:  J Infect Dis       Date:  2004-10-28       Impact factor: 5.226

3.  Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV.

Authors:  M Connors; P L Collins; C Y Firestone; A V Sotnikov; A Waitze; A R Davis; P P Hung; R M Chanock; B R Murphy
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

4.  Mortality associated with influenza and respiratory syncytial virus in the United States.

Authors:  William W Thompson; David K Shay; Eric Weintraub; Lynnette Brammer; Nancy Cox; Larry J Anderson; Keiji Fukuda
Journal:  JAMA       Date:  2003-01-08       Impact factor: 56.272

5.  Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis.

Authors:  P A Piedra; S Grace; A Jewell; S Spinelli; D Bunting; D A Hogerman; F Malinoski; P W Hiatt
Journal:  Pediatr Infect Dis J       Date:  1996-01       Impact factor: 2.129

6.  Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old.

Authors:  D A Tristram; R C Welliver; C K Mohar; D A Hogerman; S W Hildreth; P Paradiso
Journal:  J Infect Dis       Date:  1993-01       Impact factor: 5.226

7.  Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children.

Authors:  R B Belshe; E L Anderson; E E Walsh
Journal:  J Infect Dis       Date:  1993-10       Impact factor: 5.226

8.  Safety and immunogenicity of the PFP vaccine against respiratory syncytial virus (RSV): the western blot assay aids in distinguishing immune responses of the PFP vaccine from RSV infection.

Authors:  P A Piedra; W P Glezen; J A Kasel; R C Welliver; A M Jewel; Y Rayford; D A Hogerman; S W Hildreth; P R Paradiso
Journal:  Vaccine       Date:  1995-08       Impact factor: 3.641

9.  The burden of respiratory syncytial virus infection in young children.

Authors:  Caroline Breese Hall; Geoffrey A Weinberg; Marika K Iwane; Aaron K Blumkin; Kathryn M Edwards; Mary A Staat; Peggy Auinger; Marie R Griffin; Katherine A Poehling; Dean Erdman; Carlos G Grijalva; Yuwei Zhu; Peter Szilagyi
Journal:  N Engl J Med       Date:  2009-02-05       Impact factor: 91.245

Review 10.  Respiratory syncytial virus: current progress in vaccine development.

Authors:  Rajeev Rudraraju; Bart G Jones; Robert Sealy; Sherri L Surman; Julia L Hurwitz
Journal:  Viruses       Date:  2013-02-05       Impact factor: 5.048
View more
  2 in total

1.  A curated transcriptome dataset collection to investigate the blood transcriptional response to viral respiratory tract infection and vaccination.

Authors:  Salim Bougarn; Sabri Boughorbel; Damien Chaussabel; Nico Marr
Journal:  F1000Res       Date:  2019-03-13

2.  Lower respiratory tract infection in the community: associations between viral aetiology and illness course.

Authors:  L M Vos; R Bruyndonckx; N P A Zuithoff; P Little; J J Oosterheert; B D L Broekhuizen; C Lammens; K Loens; M Viveen; C C Butler; D Crook; K Zlateva; H Goossens; E C J Claas; M Ieven; A M Van Loon; T J M Verheij; F E J Coenjaerts
Journal:  Clin Microbiol Infect       Date:  2020-03-31       Impact factor: 8.067
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.